|
|
Novo Alle
Bagsvard, 2880 Denmark
phone:(45) 4444 8888
fax:(45) 4449 0555
|
|
| Symbol |
NVO |
| Exchange |
NYSE |
| Founded |
1989 |
| Employees |
|
|
|
| www.novonordisk.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Expertise in diabetes, haemostasis management, hormone therapy. |
|
| Management |
| Lars Rebien S?rensen, President and chief executive officer (CEO); Jesper Brandgaard, executive vice president and chief financial officer (CFO); Lise Kingo, Executive vice president and chief of staffs (COS); K?re Schultz, Executive vice president and chief operating officer (COO); Mads Krogsgaard Thomsen, Executive vice president and chief science officer (CSO) |
| |
|
|
|
|
|
|
|
| Keywords |
| metabolic disorders, insulin, haemophilia, osteoporosis, cardiovascular |
|
|
|
| Description |
|
Novo Nordisk has expertise in diabetes, haemostasis management, growth hormone therapy and hormone replacement therapy. |
|
| Products / Services |
Novo Nordisk currently market a number of products for the management and treatment of diabetes, including insulin analogues, insulin delivery systems and blood glucose monitoring and insuling calculation. The company also market products for the treatment of haemophilia, growth disorders and for hormone replacement therapy in menopausal women.
|
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members